[{"id":"cf7c9bf8-9998-421c-af0f-232e1fae07bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05227664","created_at":"2022-02-12T13:52:34.003Z","updated_at":"2024-07-02T16:36:04.108Z","phase":"Phase 2","brief_title":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT05227664","lead_sponsor":"Akeso","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Yidafan (ivonescimab) • ligufalimab (AK117)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/23/2022","start_date":" 03/23/2022","primary_txt":" Primary completion: 01/30/2023","primary_completion_date":" 01/30/2023","study_txt":" Completion: 10/30/2023","study_completion_date":" 10/30/2023","last_update_posted":"2022-09-12"},{"id":"726c31e3-f27c-4c7c-808b-3d3d8e64ea90","acronym":"","url":"https://clinicaltrials.gov/study/NCT05229497","created_at":"2022-02-12T13:52:34.813Z","updated_at":"2024-07-02T16:36:10.621Z","phase":"Phase 1/2","brief_title":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","source_id_and_acronym":"NCT05229497","lead_sponsor":"Akeso","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • 5-fluorouracil • Yidafan (ivonescimab) • ligufalimab (AK117)"],"overall_status":"Recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 05/04/2022","start_date":" 05/04/2022","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2022-05-11"}]